Orthofix Medical INC 10-Q quarterly reports

Orthofix Medical Inc. announced its second quarter 2026 financial results, showing a 3.8% increase in net sales to $210.9 million, but a net loss of $15.8 million.

Orthofix Medical Inc. reported Q1 2026 net sales of $196.7 million, a 1.6% increase year-over-year, driven by growth in Global Limb Reconstruction and Therapeutic Solutions, while navigating significant legal settlements.

Orthofix Medical Inc. reported increased net sales and a narrower net loss in Q3 2025, driven by growth in Global Orthopedics and Bone Growth Therapies, despite significant legal expenses and the discontinuation of M6 product lines.

Orthofix Medical Inc. reported a significantly reduced net loss and positive free cash flow for Q2 2025, driven by sales growth and improved operational efficiency, despite ongoing legal challenges and the impairment of its M6 product lines.

Orthofix Medical Inc. reports a net loss for Q1 2025, influenced by the discontinuation of its M6 product line, while highlighting growth in other segments.

Orthofix Medical Inc. saw a 7% increase in net sales in the third quarter of 2024 and secured a new $275 million credit facility.

Orthofix Medical Inc. announced a 6% increase in net sales for the second quarter of 2024, driven by strong growth in Bone Growth Therapies and U.S. Spine Fixation.

Orthofix Medical Inc. announced a 7.7% increase in net sales for the first quarter of 2024, alongside a net loss of $36 million and several executive leadership changes.